Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.4 (market cap $41.13B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 4.1× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IEF | XBI | |
|---|---|---|
Market Cap | $41.13B | $10.11B |
Volume | 10,340,382 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $97.99 | $169.55 |
52-Week Low | $88.92 | $104.99 |
Typical Hold Time | 108 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.45, up 0.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 52.94, while ADX indicates strong bearish momentum. Recent dividend payments of $0.31-$0.33 provide income support amid challenging bond market conditions. Key support sits at $89 with resistance at $90, creating a tight trading range.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current levels may offer entry points for income-focused investors, persistent inflation and Fed policy uncertainty pose significant risks. The bearish technical setup suggests continued pressure unless macroeconomic conditions improve.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
